ReviewNature reviews. Clinical oncology2025
Minimal residual disease as a target for liquid biopsy in patients with solid tumours.
Review in Nature reviews. Clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed.
- Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).BMC cancer · 2025Trial
- Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN.Cancer biology & therapy · 2026Article
- Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects.Signal transduction and targeted therapy · 2026Review
- Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.Blood advances · 2026Review
- AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.International journal of clinical oncology · 2026Review
- Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.American journal of clinical dermatology · 2026Review
- Clinical value of blood circulating tumor RNA (ctRNA) in liquid biopsy of lung cancer: a narrative review.Translational lung cancer research · 2026Review
- Circulating tumor DNA clearance as a trial-level early efficacy signal in solid tumors: a systematic review and meta-analysis of randomized trials.Translational cancer research · 2026Article
- Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?Journal of personalized medicine · 2026Review
- Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026Review
- Liquid biopsy in colorectal cancer: redefining surgical decision-making.Updates in surgery · 2026Review
- Article
- Circulating Mitochondrial DNA Measures Across Malignancies: Diagnostic Accuracy and Prognostic Associations.Cancer medicine · 2026Article
- Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring.Genome medicine · 2026Review
- Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.European journal of haematology · 2026Review
- Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Toward generalizable prediction of cancer signal using a cell-free DNA language model.Cell reports. Medicine · 2026Article
- Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is the leading cause of cancer-related death in patients with solid tumours. Current imaging technologies are not sufficiently sensitive to detect minimal residual disease (MRD; also known as measurable or molecular residual disease) after initial surgery or chemotherapy, pointing to the need for more sensitive tests to detect remaining traces of cancer in the body. Liquid biopsy, or the analysis of tumour-derived or tumour-induced cells or cellular products in the blood or other body fluids, has opened a new diagnostic avenue to detect and monitor MRD. Liquid biopsy is already used in clinical decision making for patients with haematological malignancies. Here, we review current knowledge on the use of circulating tumour DNA (ctDNA) to detect and monitor MRD in patients with solid tumours. We also discuss how ctDNA-guided MRD detection and characterization could herald a new era of novel 'post-adjuvant therapies' with the potential to eliminate MRD and cure patients before terminal metastatic disease is evident on imaging.
Indexed as
Identifiers
39609625What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.